High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa

Molecular Genetics and Metabolism

Volumn 101, Issue 4, 2010, Pages 338-345

  de Vries, Juna M ^a,b   van der Beek, Nadine A M E ^a   Kroos, Marian A ^a   Özkan, Lale ^a   van Doorn, Pieter A ^a   Richards, Susan M ^c   Sung, Crystal C C ^c   Brugma, Jan Dietert C ^a   Zandbergen, Adrienne A M ^a   van der Ploeg, Ans T ^b   Reuser, Arnold J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c GENZYME CORPORATION   (United States)

Author keywords

Glucosidase; Alglucosidase alfa; Infusion associated reaction; Lysosomal storage disorder; Neutralizing antibody; Pompe disease

Indexed keywords

ALPHA GLUCOSIDASE; DNA; HYDROCORTISONE; NEUTRALIZING ANTIBODY; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHILL; DISEASE COURSE; DNA DETERMINATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; FEMALE; FEVER; FIBROBLAST; GENOTYPE; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LYSOSOME STORAGE DISEASE; MALAISE; MALE; MUSCLE STRENGTH; ONSET AGE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ALPHA-GLUCOSIDASES; ANTIBODIES; ENZYME REPLACEMENT THERAPY; FEMALE; FIBROBLASTS; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; IMMUNOLOGIC TESTS; MALE; MIDDLE AGED; MUSCLE STRENGTH; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 78649323564     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.08.009     Document Type: Article

References (39)

1. Hers H.G. alpha-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). Biochem. J. 1963, 86:11-16.
2. Hirschhorn R., Reuser A.J.J. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, 3389-3420. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly (Eds.).
3. van der Ploeg A.T., Reuser A.J. Pompe's disease. Lancet 2008, 372:1342-1353.
4. Engel A.G., Hirschhorn R., Huie M.L. Acid maltase deficiency. Myology 2004, 1559-1586. A. Engel (Ed.).
5. Van den Hout H.M., Hop W., Van Diggelen O.P., Smeitink J.A., Smit G.P., Poll-The B.T., Bakker H.D., Loonen M.C., de Klerk J.B., Reuser A.J.J., Van der Ploeg A.T. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003, 112:332-340.
6. Kishnani P.S., Hwu W.L., Mandel H., Nicolino M., Yong F., Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 2006, 148:671-676.
7. Zhao H., Bailey L.A., Grabowski G.A. Enzyme therapy of Gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol. Dis. 2003, 30:90-96.
8. Starzyk K., Richards S., Yee J., Smith S.E., Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol. Genet. Metab. 2007, 90:157-163.
9. Hollak C.E., Linthorst G.E. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?. Mol. Genet. Metab. 2009, 96:1-3.
10. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Sidman M., Kakkis E.D., Cox G.F. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009, 123:229-240.
11. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 2006, 8:465-473.
12. Richards S. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders. Clin. Appl. Immunol. Rev. 2002, 2:241-253.
13. Kishnani P.S., Nicolino M., Voit T., Rogers R.C., Tsai A.C., Waterson J., Herman G.E., Amalfitano A., Thurberg B.L., Richards S., Davison M., Corzo D., Chen Y.T. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J. Pediatr. 2006, 149:89-97.
14. Nicolino M., Byrne B., Wraith J.E., Leslie N., Mandel H., Freyer D.R., Arnold G.L., Pivnick E.K., Ottinger C.J., Robinson P.H., Loo J.C., Smitka M., Jardine P., Tato L., Chabrol B., McCandless S., Kimura S., Mehta L., Bali D., Skrinar A., Morgan C., Rangachari L., Corzo D., Kishnani P.S. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 2009, 11:210-219.
15. van der Ploeg A.T., Clemens P.R., Corzo D., Escolar D.M., Florence J., Groeneveld G.J., Herson S., Kishnani P.S., Laforet P., Lake S.L., Lange D.J., Leshner R.T., Mayhew J.E., Morgan C., Nozaki K., Park D.J., Pestronk A., Rosenbloom B., Skrinar A., van Capelle C.I., van der Beek N.A., Wasserstein M., Zivkovic S.A. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N. Engl. J. Med. 2010, 362:1396-1406.
16. Kishnani P.S., Goldenberg P.C., Dearmey S.L., Heller J., Benjamin D., Young S., Bali D., Smith S.A., Li J.S., Mandel H., Koeberl D., Rosenberg A., Chen Y.T. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 2010, 99:26-33.
17. Case L.E., Koeberl D.D., Young S.P., Bali D., Dearmey S.M., Mackey J., Kishnani P.S. Improvement with ongoing enzyme replacement therapy in advanced late-onset Pompe disease: a case study. Mol. Genet. Metab. 2008, 95:233-235.
18. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F.X., Vielhaber S., Brejova A., Hilz M., Reiners K., Muller-Felber W., Mengel E., Spranger M., Schoser B. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 2010, 257:91-97.
19. Winkel L.P., Van den Hout J.M., Kamphoven J.H., Disseldorp J.A., Remmerswaal M., Arts W.F., Loonen M.C., Vulto A.G., Van Doorn P.A., De Jong G., Hop W., Smit G.P., Shapira S.K., Boer M.A., van Diggelen O.P., Reuser A.J., Van der Ploeg A.T. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann. Neurol. 2004, 55:495-502.
20. van Capelle C.I., Winkel L.P., Hagemans M.L., Shapira S.K., Arts W.F., van Doorn P.A., Hop W.C., Reuser A.J., van der Ploeg A.T. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul. Disord. 2008, 18:447-452.
21. Rossi M., Parenti G., Della Casa R., Romano A., Mansi G., Agovino T., Rosapepe F., Vosa C., Del Giudice E., Andria G. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from Chinese hamster ovary cells. J. Child Neurol. 2007, 22:565-573.
22. Kapica-Topczewska K., Tarasiuk J., Kulakowska A., Drozdowski W. A case of Pompe disease treated with acid alpha-glucosidase. Neurol. Neurochir. Pol. 2008, 42:353-357.
23. van der Ploeg R.J., Fidler V., Oosterhuis H.J. Hand-held myometry: reference values. J. Neurol. Neurosurg. Psychiatry 1991, 54:244-247.
24. Wokke J.H., Escolar D.M., Pestronk A., Jaffe K.M., Carter G.T., van den Berg L.H., Florence J.M., Mayhew J., Skrinar A., Corzo D., Laforet P. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008, 38:1236-1245.
25. Anon Muscular weakness assessment: use of normal isometric strength data. The National Isometric Muscle Strength (NIMS) Database Consortium. Arch. Phys. Med. Rehabil. 1996, 77:1251-1255.
26. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., Crapo R., Enright P., van der Grinten C.P., Gustafsson P., Jensen R., Johnson D.C., MacIntyre N., McKay R., Navajas D., Pedersen O.F., Pellegrino R., Viegi G., Wanger J. Standardisation of spirometry. Eur. Respir. J. 2005, 26:319-338.
27. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur. Respir. J. Suppl. 1993, 16:5-40.
28. Wilson S.H., Cooke N.T., Edwards R.H., Spiro S.G. Predicted normal values for maximal respiratory pressures in Caucasian adults and children. Thorax 1984, 39:535-538.
29. Zapletal A., Samanek M., Paul T. Lung function in children and adolescents. Methods, reference values. Prog. Respir. Res. 1987, 22:113-218.
30. van Diggelen O.P., Oemardien L.F., van der Beek N.A., Kroos M.A., Wind H.K., Voznyi Y.V., Burke D., Jackson M., Winchester B.G., Reuser A.J. Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates. J. Inherit. Metab. Dis. 2009, 32:416-423.
31. Kroos M.A., Pomponio R.J., Hagemans M.L., Keulemans J.L., Phipps M., DeRiso M., Palmer R.E., Ausems M.G., Van der Beek N.A., Van Diggelen O.P., Halley D.J., Van der Ploeg A.T., Reuser A.J. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology 2007, 68:110-115.
32. Van Diggelen O.P., Zhao H., Kleijer W.J., Janse H.C., Poorthuis B.J., van Pelt J., Kamerling J.P., Galjaard H. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). Clin. Chim. Acta 1990, 187:131-139.
33. Hermans M.M.P., Kroos M.A., Smeitink J.A.M., van der Ploeg A.T., Kleijer W.J., Reuser A.J.J. Glycogen storage disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry. Hum. Mutat. 1998, 11:209-215.
34. Huie M.L., Chen A.S., Tsujino S., Shanske S., DiMauro S., Engel A.G., Hirschhorn R. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T->G) mutation in a majority of patients and a novel IVS10 (+1GT->CT) mutation. Hum. Mol. Genet. 1994, 3:2231-2236.
35. Raben N., Nichols R.C., Martiniuk F., Plotz P.H. A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Hum. Mol. Genet. 1996, 5:995-1000.
36. Amalfitano A., Bengur A.R., Morse R.P., Majure J.M., Case L.E., Veerling D.L., Mackey J., Kishnani P., Smith W., McVie-Wylie A., Sullivan J.A., Hoganson G.E., Phillips J.A., Schaefer G.B., Charrow J., Ware R.E., Bossen E.H., Chen Y.T. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 2001, 3:132-138.
37. Van den Hout J.M., Kamphoven J.H., Winkel L.P., Arts W.F., De Klerk J.B., Loonen M.C., Vulto A.G., Cromme-Dijkhuis A., Weisglas-Kuperus N., Hop W., Van Hirtum H., Van Diggelen O.P., Boer M., Kroos M.A., Van Doorn P.A., Van der Voort E., Sibbles B., Van Corven E.J., Brakenhoff J.P., Van Hove J., Smeitink J.A., de Jong G., Reuser A.J., Van der Ploeg A.T. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004, 113:e448-e457.
38. Ohashi T., Iizuka S., Ida H., Eto Y. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol. Genet. Metab. 2008, 94:313-318.
39. Mendelsohn N.J., Messinger Y.H., Rosenberg A.S., Kishnani P.S. Elimination of antibodies to recombinant enzyme in Pompe's disease. N. Engl. J. Med. 2009, 360:194-195.